AK139 for Chronic Rhinosinusitis With Nasal Polyps
Tests AK139 injections against placebo in adults with chronic rhinosinusitis with nasal polyps.
Key facts
- Who runs it
- Akeso
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 75 people, planned
- Started
- 10 Aug 2026
- Expected to end
- 31 Jul 2027
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- AK139
- Placebo
- Record updated
- 10 August 2026
Who can take part
The trial is looking for adults with long-term sinus inflammation and nasal polyps (growths) in both sides of the nose. Participants also use a steroid nose spray (mometasone furoate) during the trial.
- Age
- 18 to 75 years
- Sex
- All sexes
- Disease stage
- Nasal polyps in both sides of the nose. Nasal Polyp Score (NPS) of 5 or more, with at least 2 on each side. Ongoing blocked nose, with a Nasal Congestion Score (NCS) of 2 or 3.
- Earlier treatment
- Must have had steroid tablets or injections (systemic corticosteroids), or be unable to take them, and/or had nasal polyp surgery before. Must have used a steroid nose spray for at least 4 weeks before screening. Cannot have had certain biologic drugs within 10 weeks or 5 half-lives (whichever is longer), or AK139 before.
- Main reasons for not taking part
- Sinus or nose surgery within 6 months before screening
- Asthma with FEV1 (a lung test) of 50% or less of the expected value
- Chronic hepatitis B, hepatitis C, HIV or syphilis; active tuberculosis or autoimmune disease
- Systemic steroids within 4 weeks (short or medium acting) or 6 weeks (long acting) before screening
- Earlier anti-IL-4Rα antibody treatment that did not work well enough
Show the full registry criteria (17)Hide the full registry criteria
Who can take part
- Male or female participants aged 18 to 75 years (inclusive) at the time of signing the informed consent form (ICF)
- Bilateral CRSwNP with prior treatment with systemic corticosteroids (SCS), contraindications to or intolerance of SCS, and/or prior nasal polyp surgery
- Nasal Polyp Score (NPS) ≥5, with a minimum score of 2 in each nasal cavity, at screening and baseline
- Ongoing nasal congestion/obstruction, with a Nasal Congestion Score (NCS) of 2 or 3 at screening and baseline
- Use of intranasal corticosteroids for at least 4 weeks prior to screening
Who cannot take part
- History of sinonasal surgery (including nasal polypectomy) within 6 months prior to screening, or prior nasal surgery resulting in structural changes that preclude adequate assessment of Nasal Polyp Score (NPS)
- Acute sinusitis, nasal infection, or upper respiratory tract infection within 2 weeks prior to screening or during the screening period
- Treatment with anti-IL-4Rα monoclonal antibodies, anti-thymic stromal lymphopoietin (TSLP) monoclonal antibodies, anti-immunoglobulin E (IgE) monoclonal antibodies, or other biologic agents within 10 weeks or 5 half-lives (whichever is longer) before randomization, or prior treatment with AK139
- Treatment with short- or intermediate-acting systemic corticosteroids within 4 weeks prior to screening, or long-acting systemic corticosteroids within 6 weeks prior to screening
- Prior treatment with anti-IL-4Rα monoclonal antibodies with inadequate clinical response
- Presence of any of the following conditions:; Antrochoanal polyp; Persistent rhinitis medicamentosa; Allergic fungal rhinosinusitis with symptoms and/or CT findings
- Nasal malignant or benign tumors
- Known eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, cystic fibrosis, primary ciliary dyskinesia, or other systemic diseases associated with nasal polyposis
- Parasitic infection, active tuberculosis, recurrent or chronic infectious diseases, or autoimmune diseases
- Chronic infection with hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), or syphilis
- Severe nasal septal deviation causing obstruction of at least one nostril
- Participants with asthma and FEV1 ≤50% of the predicted value at screening or baseline
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Chronic rhinosinusitis with nasal polyps
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AK139 injection compared with placebo in participants with chronic rhinosinusitis with nasal polyps (CRSwNP) receiving background treatment with mometasone furoate nasal spray (MFNS).
The 3 groups in the trial
- AK139 regimen 1Treatment being tested
AK139 regimen 1 will be administered by subcutaneous injection
Treatment: AK139
- AK139 regime 2Treatment being tested
AK139 regime 2 will be administered by subcutaneous injection.
Treatment: AK139
- PlaceboPlacebo, for comparison
Placebo will be administered by subcutaneous injection.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps
- Plain-language title
- AK139 for Chronic Rhinosinusitis With Nasal PolypsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07755371, who can take part
- Record updated
- 10 August 2026